Comparison of NSG-Quad and MISTRG-6 humanized mice for modeling circulating and tumor-infiltrating human myeloid cells

Humanized mice are valuable preclinical models for immuno-oncology research because they allow modeling of human immune cells and human tumors <i>in vivo</i>. Myeloid cells are highly abundant in many tumors and have been associated with tumor progression, metastasis, and therapy resistance. Next-generation humanized mice have been generated to improve the development, diversity, and function of human myeloid cells. In this study, we analyzed human immune cell development and myeloid cell composition in NSG-Quad and MISTRG-6 mice. NSG-Quad mice supported the development of tissue-resident and tumor-infiltrating human macrophages at levels almost comparable to those of MISTRG-6 mice. However, the development of human CD4<sup>+</sup> and CD8<sup>+</sup> T cells was impaired in the blood and spleen but not in the tumor of NSG-Quad mice. In a subset of NSG-Quad mice, human monocytes exhibited increased cellular granularity and elevated expression of activation and checkpoint molecules, consistent with a monocyte hyperactivation syndrome. Our study provides a comprehensive comparative analysis of the frequency and characteristics of circulating, tissue-resident, and tumor-infiltrating myeloid cell populations in NSG-Quad and MISTRG-6 mice, which is key to accurately design and interpret human tumor xenograft studies, particularly with regard to faithful reconstruction of the human tumor-immune microenvironment and preclinical testing.

Authors

Institutions

Publication Details

Journal
Molecular Therapy — Methods & Clinical Development
Published
2025-05-14
DOI
https://doi.org/10.1016/j.omtm.2025.101487
Citations
1
Primary Topic
Immune cells in cancer
Type
article
Field-Weighted Citation Impact
0.80

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Comparison of NSG-Quad and MISTRG-6 humanized mice for modeling circulating and tumor-infiltrating human myeloid cells

Christine Brostjan, Viktoria Knöbl, Carmen Stecher, Nina Braun et al.
1 citations
Molecular Therapy — Methods & Clinical Development
Immune cells in cancer
0.80
article

Comparison of NSG-Quad and MISTRG-6 humanized mice for modeling circulating and tumor-infiltrating human myeloid cells

Christine Brostjan, Viktoria Knöbl, Carmen Stecher, Nina Braun, Magdalena Frank, Anna Chen, Dietmar Herndler‐Brandstetter, Johannes M. Reisecker, Alex Farr, Joerg Hauser, Ines Neuwirth, Oliver Walzer, Semina Duvnjak
article en
1 citations

Abstract

Humanized mice are valuable preclinical models for immuno-oncology research because they allow modeling of human immune cells and human tumors <i>in vivo</i>. Myeloid cells are highly abundant in many tumors and have been associated with tumor progression, metastasis, and therapy resistance. Next-generation humanized mice have been generated to improve the development, diversity, and function of human myeloid cells. In this study, we analyzed human immune cell development and myeloid cell composition in NSG-Quad and MISTRG-6 mice. NSG-Quad mice supported the development of tissue-resident and tumor-infiltrating human macrophages at levels almost comparable to those of MISTRG-6 mice. However, the development of human CD4<sup>+</sup> and CD8<sup>+</sup> T cells was impaired in the blood and spleen but not in the tumor of NSG-Quad mice. In a subset of NSG-Quad mice, human monocytes exhibited increased cellular granularity and elevated expression of activation and checkpoint molecules, consistent with a monocyte hyperactivation syndrome. Our study provides a comprehensive comparative analysis of the frequency and characteristics of circulating, tissue-resident, and tumor-infiltrating myeloid cell populations in NSG-Quad and MISTRG-6 mice, which is key to accurately design and interpret human tumor xenograft studies, particularly with regard to faithful reconstruction of the human tumor-immune microenvironment and preclinical testing.

Molecular Therapy — Methods & Clinical DevelopmentVol. 33(2)
Comprehensive Cancer Center Vienna (AT), Medical University of Vienna (AT)
Vienna Science and Technology Fund, Austrian Science Fund
Openalex Percentile: Top 28%
Immune cells in cancer
0.80
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.